Cetuximab (Erbitux) News, Updated Regularly

YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED - MSN MoneyCentral
January 5, 2009, 2:07 pm

MISSISSAUGA, ON , Jan. 5 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Alternext US:YMI, TSX:YM, AIM:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that it ...

Advocates push 'personalized medicine' - United Press International
December 30, 2008, 6:14 am

WASHINGTON, Dec. 30 (UPI) -- Most drugs work for only about half the people who take them, spurring a push to improve healthcare through "personalized medicine," U.S. researchers say. Personalized medicine, involving genetic screening and other tests ...

New bowel cancer therapy up for subsidy - ninemsn
January 1, 2009, 4:25 am

Australians with advanced bowel cancer may soon get subsidised access to a drug that only works on people with a specific genetic make-up. The drug, called Erbitux, is one of a growing number of targeted cancer therapies like the breast cancer ...

Will a pill work for you? Genes hold the answer - Raleigh News & Observer
December 30, 2008, 1:21 am

For more than two years, Jody Uslan had been taking the drug tamoxifen in the hope of preventing a recurrence of breast cancer. Then a new test suggested that because of her genetic makeup, the drug was not doing her any good. "I was devastated ...

Genetic tests offer promise of personalized medicine - International Herald Tribune
December 29, 2008, 10:08 pm

For more than two years, Jody Uslan had been taking the drug tamoxifen in hopes of preventing a recurrence of breast cancer. Then a new test suggested that because of her genetic makeup, the drug was not doing her any good. "I was devastated," said ...

Tests hold the promise of personalized drugs - Herald Tribune
December 30, 2008, 6:22 am

For more than two years, Jody Uslan had been taking the drug tamoxifen in hopes of preventing a recurrence of breast cancer. Then a new test suggested that because of her genetic makeup, the drug was not doing her any good. Click to enlarge NEW YORK ...

Genetic tests offer ?personalized? medicine - Providence Journal
January 2, 2009, 6:21 pm

For more than two years, Jody Uslan had been taking the drug tamoxifen in hopes of preventing a recurrence of breast cancer. Then a new test suggested that because of her genetic makeup, the drug was not doing her any good. NYT / Marissa Roth For ...

Patient?s DNA May Be Signal to Tailor Medication - Star News Online
December 30, 2008, 2:00 pm

For more than two years, Jody Uslan had been taking the drug tamoxifen in hopes of preventing a recurrence of breast cancer. Then a new test suggested that because of her genetic makeup, the drug was not doing her any good. ?I was devastated ...

Register for FREE - Wall Street Journal
December 30, 2008, 12:55 pm

Please register to gain free access to WSJ tools. An account already exists for the email address entered. When Deal Journal told people we were going to cover an event honoring the 25 Most Powerful Women in Banking, a common reaction was: ?There ...

Merck Serono: Study Published in JCO Shows Erbitux Enhances - PharmiWeb
January 5, 2009, 3:30 am

Darmstadt, January 05, 2009 ? A study published today in the Journal of Clinical Oncology demonstrates that the addition of Erbitux® (cetuximab) to standard oxaliplatin-based chemotherapy (FOLFOX-4) in previously untreated metastatic colorectal ...

Are you looking for additional Erbitux (Cetuximab) news? Try our new "Cetuximab News Focus" area.

Are you looking for additional Erbitux (Cetuximab) information? Try our new "Cetuximab Related Blog Entries" area.

Off-site Cetuximab (Erbitux) Links, User Submitted

The following links have been collected through user bookmark submission in the Cetuximab_Erbitux category. Please note, because these resources are off-site we cannot guarantee the accuracy or quality of any information.

Tue Dec 9

• Competitor - Erbitux - Cetuximab - US label with safety information and side effects
• Competitor - Cetuximab (Erbitux) - Cytotoxicity and mechanism of action
• Competitor - Bristol Myers Squibb - Cetuximab - Wikipedia - $30,000 for 8 weeks intravenous treatment

Fri Aug 15

• Patient Information Sheet: Cetuximab (marketed as Erbitux)
• Successful Treatment of Recurrent Squamous Cell Carcinoma of the Skin with Cetuximab
• Cetuximab: a review of its use in squamous cell ca...[Drugs. 2007] - PubMed Result

Sun Jul 6

• KRAS Mutations and Primary Resistance of Lung Adenocarcinoma s to Gefitinib or Erlotinib: A most important article in segmenting treatment to EGFR inhibitors in NSCLC

Sat Jun 28

• Cetuximab improved overall survival in colorectal cancer patients in whom other treatments had failed- ACP Journal Club: Jonker DJ, O?Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357:2040- 8.

Mon Jun 23

• Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

Fri Apr 18

• Current Status of Cetuximab for the Treatment of Patients with Solid Tumors -- Frieze and McCune 40 (2): 241 -- The Annals of Pharmacotherap y

Wed Jan 30

• Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk: a remarkable result - cetuximab activates EGFR but keeps it at the membrane, which may inhibit signaling to Akt or Erk in some cells!

Tue Jan 1

• NEJM -- Cetuximab for the Treatment of Colorectal Cancer

Mon Apr 9

• Monoclonal antibodies - Wikipedia, the free encyclopedia: Monoclonal antibodies (mAb) are antibodies that are identical because they were produced by one type of immune cell and are all clones of a single parent cell. Given (almost) any substance, it is possible to create monoclonal antibodies that specifically

Wed Jan 10

• ImClone Systems Incorporated (IMCL) And Bristol-Myers Squibb Company (BMY) Release: ERBITUX(R) Phase III Study Meets Primary Endpoint In First-Line Treatment Of Metastatic Colorectal Cancer

Thu Oct 19

• Entrez PubMed

Off-site Cetuximab Research Links

If you still need additional information on Cetuximab then we suggest the following off-site resources. Please note, because these resources are off-site we cannot guarantee the accuracy or quality of any information.